Acute Lymphoblastic Leukemia is a type of cancer which affects white blood cells. It is also called as Acute lymphocytic leukemia. IALL progresses rapidly without treatment. Acute lymphoblastic leukemia (ALL) is a malignant (clonal) disease of the bone marrow in which early lymphoid precursors proliferate and replace the normal hematopoietic cells of the marrow. Symptoms of ALL includes fever, anemia, bleeding, blood clots, bone pain, rashes on skin, Palpable lymphadenopathy etc. ALL is diagnosed by coagulation studies, blood tests, X-Ray, CT-Scan, ECG, MRI, bone marrow aspiration and biopsy etc. Treatment of ALL includes induction chemotherapy, consolidation chemotherapy, Stem cell transplantation and others.
In March 2015, Novartis Pharmaceuticals commenced Phase IIIb Multicenter, open-label, single arm study to evaluate the efficacy and safety of Pasireotide in Patients with acromegaly inadequately controlled with first generation somatostatin analogues.